VJHemOnc is committed to improving our service to you

EHA 2020 | DREAMM-3: belantamab mafodotin vs pom/dex for R/R myeloma

VJHemOnc is committed to improving our service to you

Katja Weisel

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses DREAMM-3, a Phase III, open-label, randomized study of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter